ArticleBlood2016
CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.
Erratum issuedOpen access · bronzeAbstract readLetter
In one paragraph
Article in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 57 citations in OpenAlex.
- Trial
- Omics and artificial intelligence integration for stratifying blast crisis CML using COSMIC signatures and pan-cancer precision drug repurposing.World journal of clinical oncology · 2025Article
- Colony-Stimulating Factor 3 Receptor Mutations and Variants in Hematological Malignancies.Cancers · 2025Review
- Expression of Aldehyde Dehydrogenase 1A1 in Relapse-Associated Cells in Acute Myeloid Leukemia.Cells · 2025Review
- Distribution of different classes of CSF3R mutations and co-mutational pattern in 360 myeloid neoplasia.Annals of hematology · 2025Article
- Gene Expression ofInternational journal of molecular sciences · 2024Article
- CSF3R T618I Collaborates With RUNX1-RUNX1T1 to Expand Hematopoietic Progenitors and Sensitizes to GLI Inhibition.HemaSphere · 2023Article
- A novel colony stimulating factor 3 receptor activating mutation identified in a patient with chronic neutrophilic leukemia.Haematologica · 2023Article
- Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- RUNX1::ETO translocations must precede CSF3R mutations to promote acute myeloid leukemia development.Leukemia · 2023Article
- [Restratifying the prognosis of acute myeloid leukemia patients with CEBPA double mutations based on CSF3R mutations and measurable residual disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Acute Myeloid Leukemia WithFrontiers in oncology · 2022Review
- Leukemia-associated truncation of granulocyte colony-stimulating factor receptor impacts granulopoiesis throughout the life-course.Frontiers in immunology · 2022Article
- A systematic analysis of genetic interactions and their underlying biology in childhood cancer.Communications biology · 2021Article
- Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics.Cancers · 2021Review
- The Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis.Cold Spring Harbor perspectives in medicine · 2021Review
- Chinese Cases of Metachromatic Leukodystrophy with the Novel Missense Mutations in ARSA Gene.Journal of molecular neuroscience : MN · 2021Article
- Prognostic Nomogram for Acute Myeloid Leukemia Patients With Biallelic CEBPA Mutations.Frontiers in oncology · 2021Article
- Companion gene mutations and their clinical significance in AML with double mutant CEBPA.Cancer gene therapy · 2020Article
- Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
24 authors at 6 institutions in 2 countries.
Julia E MaxsonClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
Rhonda E RiesClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
Yi-Cheng WangChildren's Oncology Group, Monrovia, CA;
Robert B GerbingChildren's Oncology Group, Monrovia, CA;
E Anders KolbNemours Center for Cancer and Blood Disorders, Alfred I. duPont Hospital for Children, Wilmington, DE;
Sarah L ThompsonClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
Jaime M Guidry AuvilOffice of Cancer Genomics, National Cancer Institute, Bethesda, MD;
Marco A MarraCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada;
Yussanne MaCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada;
Zusheng ZongCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada;
Andrew J MungallCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada;
Richard MooreCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada;
William LongCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada;
Patee GesuwanOffice of Cancer Genomics, National Cancer Institute, Bethesda, MD;
Tanja M DavidsenOffice of Cancer Genomics, National Cancer Institute, Bethesda, MD;
Leandro C HermidaOffice of Cancer Genomics, National Cancer Institute, Bethesda, MD;
Seamus B HughesClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
Jason E FarrarArkansas Children's Hospital Research Institute and Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR;
Jerald P RadichClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
Malcolm A SmithCancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD;
Daniela S GerhardOffice of Cancer Genomics, National Cancer Institute, Bethesda, MD;
Alan S GamisChildren's Oncology Group, Monrovia, CA; Division of Hematology/Oncology/Bone Marrow Transplantation, Children's Mercy Hospitals and Clinics, Kansas City, MO; and.
Todd A AlonzoChildren's Oncology Group, Monrovia, CA; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Soheil MeshinchiClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Children's Oncology Group, Monrovia, CA;
Canada's Michael Smith Genome Sciences Centre · CAFred Hutch Cancer Center · USNational Cancer Institute · USChildren's Oncology Group · USCenter for Cancer and Blood Disorders · USUniversity of Arkansas for Medical Sciences · US
Funding
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MBiology/prognostic implications of Flt3 mutations in AMLR01CA114563 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MESHINCHI, SOHEIL · 2005 to 2016
$4.4MPathogenic Mechanisms of CSF3R Mutations in LeukemiaR00CA190605 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI MAXSON, JULIA E · 2016 to 2018
$733kFHCRC High-Performance Computing ClusterS10OD020069 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KOOPERBERG, CHARLES L · 2015 to 2015
$600kNCI NIH HHS R00 CA190605NCI NIH HHS R01 CA114563NCI NIH HHS U10 CA180899NIH HHS S10 OD020069
Abstract
PubMed holds no abstract for this paper.
Indexed as
MutationCCAAT-Enhancer-Binding ProteinsChildChild, PreschoolCohort StudiesFemaleHumansInfantLeukemia, Myeloid, AcuteMaleReceptors, Colony-Stimulating FactorCCAAT-Enhancer-Binding ProteinsCEBPA protein, humanCSF3R protein, humanReceptors, Colony-Stimulating Factor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.